Keeping up with Cancer Immunotherapy - Monthly Roundups by Iris
Cancer Immunotherapy news, once a month, in about five minutes: immune checkpoint inhibitors, CAR-T and cell therapy, cancer vaccines and neoantigens, bispecific antibodies, immuno-oncology trial readouts and approvals, and immunotherapy biomarkers and resistance. Every story links to its sources.
Latest: October 2026
MOIO trial fails to establish 12-week checkpoint dosing
- MOIO did not establish non-inferiority for checkpoint inhibitors given every 12 weeks, with a mortality hazard ratio of 2.00 versus standard schedules:
- A 30-patient phase Ib/II ECP study reported a 96.3% overall response rate in steroid-refractory immune-related adverse events, without severe adverse events:
- Early personalized-vaccine studies showed immune activity, but NeoVax manufacturing feasibility was 11% in newly diagnosed ovarian cancer and 75% in recurrent disease:
- October 20265 min listen
MOIO trial fails to establish 12-week checkpoint dosing
In this report October added useful separation between early signals and clinical evidence: a phase III dosing strategy did not clear its interim non-inferiority test, while small studies produced signals in toxicity treatment,…
- September 20265 min listen
Merck and Moderna report positive INTerpath-001 melanoma results
In this report September added a first positive phase 3 signal for individualized neoantigen therapy, alongside a new post-immunotherapy kidney-cancer option. It also sharpened the limits of unselected checkpoint treatment and pushed…
Want this for your field?
Iris builds a briefing agent around your own profile: your field, your focus areas, your context. Delivered on your schedule.